|
|
||||||||
1 From the Institute of Ophthalmology and Moorfields Eye Hospital, London; 2 St. Thomas Hospital, London; and the 3 University of Liverpool, United Kingdom.
PURPOSE. To measure vitreous levels of soluble TNF-receptors (sTNF-Rs) types I
and II in eyes with rhegmatogenous retinal detachment (RRD),
uncomplicated or complicated with proliferative vitreoretinopathy
(PVR), and in eyes with proliferative diabetic retinopathy (PDR). To
examine whether there is any relationship between vitreous levels of
sTNF-Rs and clinical features of these conditions and between vitreous
sTNF-Rs and TNF
levels and serum levels of sTNF-Rs.
METHODS. Vitreous levels of sTNF-Rs and TNF
were measured by enzyme-linked
immunosorbent assay in 30 eyes with PVR, 30 eyes with uncomplicated
RRD, and 29 eyes with PDR. Vitreous from eyes of 10 deceased donors and
9 eyes with macular holes served as control specimens. Serum levels of
sTNF-Rs were measured in 17 patients with PDR and 21 patients
with PVR.
RESULTS. Vitreous levels of sTNF-Rs I and II were increased in eyes with PVR,
RRD, and PDR when compared with control eyes (P <
0.002). However, vitreous levels of sTNF-Rs I and II were higher in
eyes with PVR than in eyes with RRD (P < 0.01) or
PDR (P < 0.03). This contrasted with the findings
that serum sTNF-Rs were higher in PDR than in PVR
(P < 0.016) and that vitreous levels of TNF
were higher in eyes with PDR than in eyes with PVR
(P < 0.0005). In PVR, vitreous sTNF-Rs levels were
associated with the duration of retinal detachment, number of previous
external operations, and grade of severity, whereas in PDR these levels
were not related to the type or duration of diabetes or its
complication with traction retinal detachment.
CONCLUSIONS. These observations suggest the existence of TNF inhibitory mechanisms
within the eye during retinal processes of inflammation and
angiogenesis. That high vitreous levels of sTNF-Rs relate to severity
of retinopathy suggests that these molecules may constitute reactive
products of inflammation. Effective control of TNF
activity by
sTNF-Rs within the retinal microenvironment may determine the outcome
and severity of retinal proliferative conditions.
This article has been cited by other articles:
![]() |
K. Coral, N. Angayarkanni, J. Madhavan, M. Bharathselvi, S. Ramakrishnan, K. Nandi, P. Rishi, N. Kasinathan, and S. Krishnakumar Lysyl Oxidase Activity in the Ocular Tissues and the Role of LOX in Proliferative Diabetic Retinopathy and Rhegmatogenous Retinal Detachment Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 4746 - 4752. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yamaji, S. Yoshida, K. Ishikawa, A. Sengoku, K. Sato, A. Yoshida, R. Kuwahara, K. Ohuchida, E. Oki, H. Enaida, et al. TEM7 (PLXDC1) in Neovascular Endothelial Cells of Fibrovascular Membranes from Patients with Proliferative Diabetic Retinopathy Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 3151 - 3157. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sugita, H. Takase, C. Taguchi, and M. Mochizuki The Role of Soluble TNF Receptors for TNF-{alpha} in Uveitis Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 3246 - 3252. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. P. Sfikakis, N. Markomichelakis, G. P. Theodossiadis, V. Grigoropoulos, N. Katsilambros, and P. G. Theodossiadis Regression of Sight-Threatening Macular Edema in Type 2 Diabetes Following Treatment With the Anti-Tumor Necrosis Factor Monoclonal Antibody Infliximab Diabetes Care, February 1, 2005; 28(2): 445 - 447. [Full Text] [PDF] |
||||
![]() |
A. Canton, E. M. Martinez-Caceres, C. Hernandez, C. Espejo, J. Garcia-Arumi, and R. Simo CD4-CD8 and CD28 Expression in T Cells Infiltrating the Vitreous Fluid in Patients With Proliferative Diabetic Retinopathy: A Flow Cytometric Analysis Arch Ophthalmol, May 1, 2004; 122(5): 743 - 749. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yoshida, A. Yoshida, T. Ishibashi, S. G. Elner, and V. M. Elner Role of MCP-1 and MIP-1{alpha} in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization J. Leukoc. Biol., January 1, 2003; 73(1): 137 - 144. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |